US panel to review Genzyme's Myozyme for late-onset Pompe disease
This article was originally published in Scrip
The US FDA's endocrinologic and metabolic drugs advisory panel will meet on October 21st to discuss Genzyme's BLA for Myozyme (alglucosidase alfa) for the treatment of late onset Pompe disease. The agency approved Myozyme in 2006 based on efficacy data in patients with infantile-onset disease, and Genzyme conducted a study in late-onset patients as a postmarketing commitment. The BLA was filed in May and is undergoing a priority review, with a November 29th user fee date. It seeks FDA approval to manufacture the enzyme-replacement therapy in a 2,000 litre bioreactor. The agency previously approved production at a 160 litre bioreactor, but the agency has determined that Myozyme produced at the two scales should be classified as different products because of differences in the carbohydrate structures. Agency approval of the BLA would result in the availability of two commercial versions of Myozyme in the US produced at different scales.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.